Lv3
340 积分 2025-06-05 加入
Unlocking the Power of Complement-Dependent Cytotoxicity: Engineering Strategies for the Development of Potent Therapeutic Antibodies for Cancer Treatments
1个月前
已完结
Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms
1个月前
已完结
Preparing serum for functional complement assays
2个月前
已完结
The Structural Basis for Recognition of Human Leukocyte Antigen Class I Molecules by the Pan-HLA Antibody W6/32
2个月前
已完结
The Structural Basis for Recognition of Human Leukocyte Antigen Class I Molecules by the Pan-HLA Antibody W6/32
2个月前
已完结
EGFR signaling pathway as therapeutic target in human cancers
4个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
10个月前
已完结
Cadonilimab: First Approval
10个月前
已完结
Enlonstobart: First Approval
10个月前
已完结
Antibody-drug conjugates: A review of cutaneous adverse effects
1年前
已完结
皖公网安备34019202002308
